Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III
melanoma. Nat. Med. https://doi. org/10.1038/s41591-018-0198-0 (2018)| Amaria, RN et al …

The prognosis for patients with stage IV melanoma has historically been extremely poor and
there have until recently been no effective treatment options. The last 3 years have seen a …

This review describes the progress that the concept of adjuvant therapies has undergone in
the last 50 years and focuses on the most recent development where an adjuvant approach …

Purpose: Neoadjuvant immunotherapy may improve the clinical outcome of regionally
advanced operable melanoma and allows for rapid clinical and pathologic assessment of …

Simple Summary The risk of relapse for stage III melanoma remains high. Subsequently,
there has been a surge of interest in the role of contemporary therapies in the neoadjuvant …

Background Pembrolizumab is a standard of care for the treatment of unresectable or
metastatic melanoma and an adjuvant treatment of melanoma with involvement of lymph …

Background The previous OpACIN and OpACIN-neo studies investigating neoadjuvant IPI
plus NIVO have demonstrated high pathologic response rates (74–78%) and favorable long …

Highlights•The immunotherapeutic treatment landscape for patients with high-risk
melanoma has increased in complexity at a rapid pace.•Neoadjuvant immunotherapy has …

Effective systemic therapies including targeted BRAF/MEK inhibition and immune
checkpoint blockade have significantly changed the treatment landscape for malignant …

TPS9585 Background: Although long term outcomes for most patients with early-stage
melanoma is excellent following surgery, patients who have high-risk features such as …